Haleon (LON:HLN) Given Buy Rating at The Goldman Sachs Group

Key Points

• Goldman Sachs Group has reaffirmed a "buy" rating for Haleon (LON:HLN) and set a price target of GBX 440, indicating a potential upside of 18.44% from the current stock price.
• The stock currently has a consensus rating of "Hold" from analysts, with one buy, one hold, and one sell rating among various broker reports.
• Haleon recently reported quarterly earnings with an EPS of GBX 8.90 and a net margin of 9.66%, forecasting 19.50 EPS for the current fiscal year.

Haleon (LON:HLN - Get Free Report)'s stock had its "buy" rating reiterated by The Goldman Sachs Group in a report released on Wednesday, Marketbeat Ratings reports. They currently have a GBX 440 price objective on the stock. The Goldman Sachs Group's target price points to a potential upside of 23.35% from the company's previous close.

Several other brokerages have also commented on HLN. JPMorgan Chase & Co. reissued an "underweight" rating on shares of Haleon in a research note on Friday, August 1st. Berenberg Bank reduced their target price on Haleon from GBX 503 to GBX 500 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a GBX 370 target price on shares of Haleon in a research note on Thursday, July 31st. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of GBX 436.67.

Haleon Stock Performance

LON HLN traded down GBX 5.90 on Wednesday, hitting GBX 356.70. 14,169,583 shares of the company's stock were exchanged, compared to its average volume of 24,042,746. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The firm's 50-day moving average price is GBX 361.82 and its two-hundred day moving average price is GBX 380.80. Haleon has a fifty-two week low of GBX 346.10 and a fifty-two week high of GBX 419.50. The firm has a market cap of £31.93 billion, a price-to-earnings ratio of 2,135.93, a P/E/G ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported GBX 8.90 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. On average, research analysts expect that Haleon will post 19.5033282 EPS for the current year.

Insider Activity at Haleon

In other news, insider Dawn Allen sold 64,329 shares of the company's stock in a transaction on Monday, June 30th. The stock was sold at an average price of GBX 376, for a total transaction of £241,877.04. 0.01% of the stock is currently owned by insiders.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.